Clinical Scorecard: Customized Drug Evaluation and Risk Profiling in Patient-Derived Gastroenteropancreatic Neuroendocrine Tumors
At a Glance
Category
Detail
Condition
Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs), including well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs)
Key Mechanisms
Tumor cell viability and signaling pathways influenced by targeted therapies (mTOR inhibitors, tyrosine kinase inhibitors, AKT/PI3K inhibitors, CDK4/6 inhibitors), DNA damage response inhibitors, chemotherapeutics, and drug repurposed agents
Target Population
Patients with metastatic and nonmetastatic GEP-NENs undergoing surgical resection, including small intestinal NETs, pancreatic NETs, and neuroendocrine carcinomas
Care Setting
Specialized oncology centers with capabilities for tumor tissue resection and ex vivo primary culture drug screening
Key Highlights
Established a standardized personalized drug screening and risk assessment platform using patient-derived GEP-NEN primary cultures.
Systematic testing of 27 agents including targeted therapies, DNA damage response inhibitors, chemotherapeutics, and repurposed drugs revealed individualized tumor responses.
Demonstrated differences in drug responsiveness between pancreatic NETs, small intestinal NETs, and neuroendocrine carcinomas, enabling prediction of individual tumor treatment response.
Guideline-Based Recommendations
Diagnosis
Histopathological classification of GEP-NENs into NETs (G1-G3) and NECs (small or large cell subtypes) using proliferative markers.
Assessment of somatostatin receptor (SSTR) expression status to guide somatostatin analogue therapy.
Management
Use of somatostatin analogues (octreotide, lanreotide) or peptide receptor radionuclide therapy for SSTR-positive tumors.
Consideration of targeted therapies such as mTOR inhibitor everolimus and tyrosine kinase inhibitors (cabozantinib, sunitinib) on a nonpersonalized basis.
Chemotherapy regimens including streptozotocin/5-fluorouracil and capecitabine/temozolomide applied without personalization.
Implementation of personalized drug screening platforms to inform individualized therapy decisions in GEP-NENs.
Monitoring & Follow-up
Evaluation of tumor response to therapies through viability assays in patient-derived primary cultures.
Immunohistochemical assessment of tumor cell composition to confirm tumor content in primary cultures.
Risks
Poor prognosis associated with metastatic GEP-NENs, especially NECs, with limited curative treatment options beyond surgery.
Potential variability in drug response necessitates individualized risk profiling to avoid ineffective treatments.
Patient & Prescribing Data
Patients with metastatic and nonmetastatic GEP-NENs, including small intestinal and pancreatic NETs and NECs.
Personalized drug screening reveals statistically significant group effects and individual responsiveness or resistance to a broad panel of agents, supporting tailored therapeutic approaches.
Clinical Best Practices
Obtain fresh tumor tissue during surgical resection for establishment of primary cultures.
Use standardized protocols for tissue processing, cell isolation, and culture to ensure reproducibility.
Apply clinically relevant drug concentrations in ex vivo assays to assess tumor-specific drug sensitivity.
Incorporate signaling pathway analyses and immunohistochemistry to complement viability data and refine treatment selection.
Leverage personalized drug screening platforms to guide precision medicine approaches in GEP-NENs.
by Christoph J Auernhammer, Katharina Wang, Umberto Maccio, Thomas Knösel, Maximilian P Hungbauer, Katharina Schilbach, Julian Maurer, Lea Peischer, Astrid Reul, Elena Kuzmenko, Edlira Luca, Julia Hamati, Diana Vetter, Jose Oberholzer, Ralph Fritsch, Karel Pacak, Ashley B Grossman, Felix Beuschlein, Martin Reincke, Constanze Hantel, Kathrin Zitzmann, Svenja Nölting
